EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Immune checkpoint biology in health & disease: Immune checkpoint biology and autoimmunity in cancer patients

Pierre Van Mol, Elena Donders, Diether Lambrechts, Els Wauters

International Review of Cell and Molecular Biology · 2024

DOI: 10.1016/bs.ircmb.2023.04.003 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Review of Cell and Molecular Biology, 2024. Verfasst von Pierre Van Mol und 3 weiteren Autor:innen. Beteiligte Einrichtung: VIB - CCB Laboratory of Translational Genetics, KU Leuven, Leuven, Belgium; Pneumology - Respiratory Oncology, University Hospitals Leuven, Leuven, B…. Hauptthemen laut MEDLINE: Antineoplastic Agents, Immunological, Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 91 Literaturangaben. Gefördert von: Stichting Tegen Kanker, Horizon 2020 Framework Programme, Eric Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immune checkpoints (ICs) play a central role in maintaining immune homoeostasis. The discovery that tumours use this physiological mechanism to avoid elimination by the immune system, opened up avenues for therapeutic targeting of ICs as a novel way of treating cancer. However, this therapy a new array of autoimmune side effects, termed immune-related adverse events (irAEs). In this narrative review, we first recapitulate the physiological function of ICs that are approved targets for cancer immunotherapy (CTLA-4, PD-(L)1 and LAG-3), as the groundwork to critically discuss current knowledge on irAEs. Specifically, we summarize clinical aspects and examine a molecular classification and predisposing factors of irAEs. Finally, we discuss irAE treatment, particularly emphasizing how molecular knowledge is changing the current treatment paradigm.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Agents, ImmunologicalNeoplasmsHumansAutoimmunityImmunotherapyBiology

Stichwörter der Autor:innen

B-cellCTLA-4ComplementCytokineCytokine therapyCytotoxic T-lymphocyte-associated protein 4Immune-related adverse eventIrAELAG-3Lymphocyte-activation gene 3PD-1PD-L1Programmed cell death protein 1Programmed death-ligand 1T-cell

Substanzen

Antineoplastic Agents, Immunological

Autor:innen und Institutionen

  • VIB - CCB Laboratory of Translational Genetics, KU Leuven, Leuven, Belgium; Pneumology - Respiratory Oncology, University Hospitals Leuven, Leuven, Belgium.
  • VIB - CCB Laboratory of Translational Genetics, KU Leuven, Leuven, Belgium.
  • Pneumology - Respiratory Oncology, University Hospitals Leuven, Leuven, Belgium. Electronic address: els.wauters@uzleuven.be.

Förderung

  • Stichting Tegen Kanker
  • Horizon 2020 Framework Programme
  • Eric Fund
  • European Commission
  • Fonds Wetenschappelijk Onderzoek
  • KU Leuven

Zitieren

APA

Van Mol, P., Donders, E., Lambrechts, D., & Wauters, E. (2024). Immune checkpoint biology in health & disease: Immune checkpoint biology and autoimmunity in cancer patients. International Review of Cell and Molecular Biology. https://doi.org/10.1016/bs.ircmb.2023.04.003

Vancouver

Van Mol P, Donders E, Lambrechts D, Wauters E. Immune checkpoint biology in health & disease: Immune checkpoint biology and autoimmunity in cancer patients. International Review of Cell and Molecular Biology. 2024. doi:10.1016/bs.ircmb.2023.04.003

BibTeX
@article{VanMol2024,
  author = {Van Mol, Pierre and Donders, Elena and Lambrechts, Diether and Wauters, Els},
  title = {Immune checkpoint biology in health & disease: Immune checkpoint biology and autoimmunity in cancer patients},
  journal = {International Review of Cell and Molecular Biology},
  year = {2024},
  doi = {10.1016/bs.ircmb.2023.04.003}
}
Kostenlos starten →